The lysophosphatidic acid (LPA) receptor LPA 1 /Edg2 is the first identified LPA receptor. Although its wide tissue distribution and biological functions have been well studied, little is known about how LPA 1 is transcriptionally regulated. In the current study, we showed that LPA 1 is a physiological target of transforming growth factor beta (TGFb)-mediated repression. In both normal and neoplastic cells, TGFb inhibits LPA 1 promoter activity, LPA 1 mRNA expression and LPA 1 -dependent chemotaxis and tumor cell invasion. Knockdown of the TGFb intracellular effector Smad3 or Smad4 with lentivirally transduced short hairpin RNA relieved these inhibitory effects of TGFb. Interestingly, the LPA 1 promoter contains two potential TGFb inhibitory elements (TIEs), each consisting of a Smad-binding site and an adjacent E2F4/5 element, structurally similar to the TIE found on the promoter of the welldefined TGFb target gene c-myc. Deletion and point mutation analyses indicate that the distal TIE located at 401 bp from the transcription initiation site, is required for TGFb repression of the LPA 1 promoter. A DNA pull-down assay showed that the À 401 TIE was capable of binding Samd3 and E2F4 in TGFb-treated cells. TGFb-induced binding of the Smad complex to the native À 401 TIE sequence of the LPA 1 gene promoter was further verified by chromatin immunoprecipitation assays. We therefore identified a novel role of TGFb in the control of LPA 1 expression and LPA 1 -coupled biological functions, adding LPA 1 to the list of TGFbrepressed target genes.
INTRODUCTION
Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol-3-phosphate) is a naturally occurring intercellular mediator of diverse biological processes, including neurogenesis, angiogenesis, wound healing, immunity and carcinogenesis. 1 LPA is produced by activated platelets during coagulation and thus is a normal constituent of serum. 2 LPA is a ligand of multiple G protein-coupled receptors. 3 The LPA 1 /Edg2, LPA 2 /Edg4 and LPA 3 /Edg7 receptors are members of the endothelial differentiation gene (Edg) family, sharing 50-57% homology in their amino-acid sequences. 3 In addition to the Edg LPA [1] [2] [3] receptors, GPR23/P2Y9/LPA 4 of the purinergic receptor family, and the related GPR92/LPA 5 and P2Y5/LPA 6 have been reported to be additional LPA receptors. [4] [5] [6] LPA 1 is expressed in most adult tissues and in embryonic cells. 3 Only minor abnormalities, such as craniofacial dysmorphism and defective sucking behavior, were found in lpa 1 -deficient mice. 7 However, more recent studies of lpa 1 À / À mice subjected to various pathophysiological conditions revealed that LPA 1 is involved in initiation of neuropathic pain, 8 embryonic and adult neurogenesis, and promotion of pulmonary and renal fibrosis. 9, 10 Some of these biological functions of LPA 1 are attributed to the motility-stimulating activity of LPA in mammalian cells. Substantial evidence indicates that LPA 1 is the primary LPA receptor subtype to mediate LPA-dependent chemotaxis and tumor cell invasion. 11 In contrast to the LPA 2 receptor that is commonly overexpressed in various cancers, [12] [13] [14] gene expression profiling studies failed to show any consensus increase in LPA 1 expression between normal and malignant cells. [15] [16] [17] [18] [19] Instead, some expression profiling or array analyses suggest decreases in LPA 1 mRNA expression in various malignancies. 15, [17] [18] [19] Several groups recently reported that LPA 1 expression is repressed by Nm23. 20, 21 Nm23 is the first identified metastasis suppressor gene that, by definition, inhibits the process of metastasis but not growth of primary tumors. 20 In human breast carcinomas, LPA 1 expression inversely correlated with that of Nm23. 21 However, little is known about how Nm23 represses LPA 1 . Furthermore, there is no evidence that LPA 1 expression is elevated in metastatic cancer compared with primary tumors. Thus, LPA 1 expression is apparently controlled by complex regulatory mechanisms involving other unrecognized activators or repressors. In the present study, we showed for the first time that transforming growth factor beta (TGFb), a platelet-derived cytokine co-present with LPA in the circulation and tumor microenvironments, represses LPA 1 gene transcription and LPA 1 -dependent motility-stimulating activity via a TGFb inhibitory element (TIE) containing both Smad and E2F4/5 binding sites on the LPA 1 gene promoter. These results represent a novel form of crosstalk between TGFb and LPA signaling.
RESULTS
TGFb inhibits expression of LPA 1 Previous studies showed that LPA stimulates production and release of TGFb, 22, 23 Figure S1A ). The treatment with TGFb for 6 h resulted in 62% and 37% decreases in LPA 1 mRNA levels in MDA-MB-231 and SKOV-3, respectively ( Figure 1a ). TGFb did not downregulate mRNA levels of other LPA receptors present in these cells (Supplementary Figure S2) . To generalize the observation of the specific inhibitory effect of TGFb on LPA 1 , we examined a panel of breast, ovarian and other cancer cell lines, including BT-549, Caov-3 and DOV-13. Treatment with TGFb induced 30-67% decreases in LPA 1 mRNA levels in these cell lines (Figure 1b) . Most of the cancer cell lines, such as BT-549, SKOV-3 and DOV-13, were resistant to the growth inhibitory effect of TGFb as we reported recently. 25 Thus, the inhibition of LPA 1 expression by TGFb was independent of the cytostatic program of TGFb. In addition, TGFb also downregulated expression of LPA 1 in normal primary and immortalized epithelial cells, such as primary mammary epithelial cells (1001-8), primary ovarian epithelial cells (NOE-71), immortalized breast epithelial cell line MCF-10A and immortalized ovarian surface epithelial cell line IOSE-29 ( Figure 1b) . In an independent project to profile transcriptional effects of TGFb in the OE33 esophageal cancer cell line, we also observed TGFbinduced decrease in LPA 1 mRNA by 45% (data not shown). The only exception to the negative regulation by TGFb was the DLD1 colon cancer cell line. DLD1 was deficient in TGFb receptor II (TbRII) as reported previously 26 and as evidenced by the inability of TGFb to induce Smad3 phosphorylation in this particular line (Figure 1c ). It is also worth noting that LPA 1 was highly expressed in DLD1 cells, 27, 28 likely as a result of the absence of TGFb-mediated repression.
TGFb attenuates LPA 1 -dependent cell migration and invasion As TGFb represses LPA 1 mRNA expression, we anticipated that TGFb would attenuate LPA 1 -dependent actions of LPA. Although each of the Edg-family LPA receptors may contribute to cell motility in certain cellular contexts, substantial evidence supports an essential and probably sufficient role for LPA 1 in driving random migration, chemotaxis and tumor cell invasion. 27, 29, 30 In breast and ovarian cancer cell lines we examined, LPA stimulated robust chemotactic responses as analyzed by the transwell assay (Figure 2a upper) . LPA also drastically promoted invasion of these cells through Matrigel (Figure 2a and DOV-13 cells (Figure 2a upper) . This trend of increase in chemotactic migration towards TGFb was not statistically significant. Nevertheless, TGFb was capable of stimulating modest but significant increases in invasion of SKOV-3 and DOV-13 cells (Figure 2a lower) . However, the ability of TGFb to stimulate invasion of breast and ovarian cancer cell lines was much weaker than that of the potent motogen LPA. Levels of TGFb receptors did not seem to correlate with the responsiveness of these cells to TGFb (Supplementary Figure S1B) .
When MDA-MB-231, SKOV-3 and Dov-13 cells were costimulated with both LPA and TGFb, TGFb significantly inhibited LPA stimulation of migration and invasion. We observed 30-50% (Figure 2b ). In all cell lines we examined, the TGFbmediated inhibition of invasion was more prominent than the effect of TGFb on migration. This was likely due to the longer incubation of the cells with TGFb during the invasion experiments. These data demonstrated that TGFb repression of LPA 1 expression was sufficient to impair LPA 1 -dependent cell migration and invasion.
TGFb represses LPA 1 expression and LPA 1 -dependent cell migration and invasion in a Smad-dependent manner Upon binding of TGFb to its receptors, both Smad-dependent and Smad-independent pathways are activated by the kinase activity of TbRs. 31 Regulatory Smads (R-Smads), such as Smad2 and Smad3, are phosphorylated by TbRs, and form heterodimer with Smad4 to translocate to the nucleus where the Smad complex regulates transcription of target genes. 32 In addition, TGFb activates TbRassociated proteins and other intracellular signaling pathways, such as MAPK, PP2A/p70S6K, RhoA and TAK1/MEKK1 to elicit Smad-independent responses to TGFb. 33 To elucidate the mechanism underlying TGFb repression of LPA 1 , we examined the possibility for the participation of the Smad-dependent pathways in the process. Smad3, but not Smad2, was reported to be the R-Smad involved in binding to TIE to downregulate TGFb target genes, most notably c-myc. 34 We therefore knocked down Smad3 expression in MDA-MB-231 and SKOV-3 cells using lentivirally transduced shRNA. Expression of Smad3 protein was efficiently silenced by Smad3 shRNA (Figure 3a) . The silencing of Smad3 reduced the inhibitory effect of TGFb on expression of LPA 1 (Figure 3b ). Furthermore, in Smad3 knockdown cells, TGFb no longer inhibited LPA-driven cell migration (Figure 3c upper) and invasion (Figure 3c lower) . These results suggest a Smad3-dependent mechanism to repress LPA 1 expression and LPA 1 -linked migration and invasion by TGFb. In further support of this, Smad3 knockdown was accompanied by considerable increases in basal and LPA-induced cell migration and invasion (Figure 3c ). Likewise, shRNA knockdown of Smad4, the co-Smad in these cells, also inhibited the effects of TGFb on LPA 1 expression and LPA 1 -dependent cell migration (Figures 3d-f) .
TGFb represses the transcriptional activity of the LPA 1 gene promoter that contains two potential TIEs The TGFb-Smad pathway both activates and represses gene transcription. There is a long list of TGFb-activated targets, such as type I collagen and cyclin-dependent kinase inhibitors p21
Cip1 and p15
Ink4b . Conversely, only a few TGFb-repressed genes have been well defined with the c-myc and Id1 being the best characterized. Downregulation of c-myc by TGFb is mediated by the Smad3-Smad4-E2F4/5-p107 complex that binds to the consensus TIE (GGCTTGGCGGGAAA), which consists of a repressive Smad binding element (SBE) 35 and an E2F binding site on the c-myc gene promoter. Different from c-myc, Id1 is inhibited by TGFb through combined effects of a SBE and a separate CREB binding site that recruits the ATF3 repressor to the Id1 gene promoter. 36 Interestingly, analysis of the human LPA 1 gene promoter sequences revealed the presence of two potential TIEs, one located at À 401 (designated À 401 TIE) and the other at À 40 (designated À 40 TIE) from the transcription initiation site (Figure 4a ). The composite TIE consisting of the Smad and E2F4/5 binding sites is present only in the LPA 1 gene promoter but not in the promoters of other LPA receptors (LPA 2-6 ) (Supplementary Figure S4 ). Between these two TIEs, there is also an SBE ( À 324 GTCT À 321) and a probable ATF site ( À 348 TGACGCTC À 341) with five out of eight nucleotides matching with the ATF consensus sequence (TGACGTCA).
We therefore cloned a 1242-bp fragment of the LPA 1 gene promoter ( À 1156 to þ 86) into the pGL2-Basic-Luc vector to construct pGL2-LPA 1 -Luc. MDA-MB-231 and SKOV-3 cells were transfected with pGL2-LPA 1 -Luc and cultured with TGFb or vehicle for 16 h before measurement of luciferase activity in cell lysates. TGFb treatment resulted in modest but consistent decrease in luciferase activity (Figure 4b and Supplementary Figure S5) . Deletion of the proximal À 401 TIE (named del in Figure 4 ) at À 366 abolished the negative effect of TGFb on the LPA 1 promoter-driven luciferase activity (Figure 4b) , suggesting that the deleted sequence containing the À 401 TIE, rather than the potential SBE-ATF3 or the further downstream À 40 TIE, is the major site for TGFb repression of LPA 1 transcription. Indeed, similar to the deletion mutant, point mutation of the À 401 TIE (GGCTTTGGCGCG to GGCTAATTCGCGC) also eliminated the repressive effect of TGFb on the LPA 1 promoter activity. However, mutation of the À 40 TIE (5 0 -GGCTTCGCGCC-3 0 to 5 0 -GGC AATTCGCC-3 0 ) only slightly reduced the effect of TGFb, which was statistically insignificant. Taken together, these experiments indicate that the À 401 TIE site is required for TGFb-Smadmediated repression of the LPA 1 gene.
Smad complex binds to the À 401 TIE of the LPA 1 promoter To gain evidence that the Smad complex binds to the LPA 1 promoter at the À 401 TIE, we performed DNA pull-down assay using biotinylated double-stranded oligonucleotides corresponding to the sequences between À 413 and À 378 that included the À 401 TIE of the LPA 1 promoter. MDA-MB-231 and SKOV-3 cells were treated for 1 h with TGFb or vehicle. The 36-bp DNA fragment was incubated with cell lysates to allow binding and precipitating Smad3 and E2F4 as detailed in Materials and methods. As demonstrated in Figure 5a , co-precipitated Smad3 and E2F4 were detected from TGFb-treated cells but not from vehicle-treated control cells, suggesting that the 36-bp DNA fragment is capable of binding active Smad3 and E2F4.
To determine if TGFb induces Smad3 and E2F4 binding to the native À 401 TIE region of the LPA 1 promoter, we performed chromatin immunoprecipitation (ChIP) assays in MDA-MB-231 and SKOV-3 cells. The qPCR analysis of Smad3 immunoprecipitates from MDA-MB-231 and SKOV-3 cells showed 3.8-and 3.7-fold induction of Smad3 binding to the À 401 TIE (Figure 5b ). We also observed 2.0-and 1.8-fold increases in Smad3 binding to the À 40 TIE in MDA-MB-231 and SKOV-3, respectively. Thus, TGFb induced physical binding of activated Smad3 to the À 401 TIE and to a lesser extent, to the À 40 TIE of the LPA 1 promoter. The binding of E2F4, another partner of the Smad complex, to the À 401 TIE also increased by 2.5-and 2.7-fold following TGFb treatment of MDA-MB-231 and SKOV-3 cells. However, no significant increase in binding of E2F4 to the À 40 TIE in TGFb-treated MDA-MB-231 cells was observed. In these ChIP experiments, we included the c-myc TIE as positive controls and confirmed the binding of Smad3 and E2F4 to the c-myc TIE in SKOV-3 cells treated with TGFb. In sum, these experiments provide mechanistic insight into the TGFbmediated repression of LPA 1 transcription and LPA 1 -linked biological activities.
DISCUSSION
In the present study, we showed that the LPA 1 gene is a direct target of TGFb-mediated repression. This inhibitory effect of TGFb on LPA 1 expression is detected in both normal and neoplastic cells with intact TbR and Smad signaling. Importantly, the inhibition of LPA 1 by TGFb is sufficient to suppress the LPA 1 -dependent migratory responses to LPA. The detailed analysis of the underlying mechanism indicates that TGFb triggers downregulation of LPA 1 through activation of Smad and binding of the Smad-E2F4 Figure 5 . TGFb induces occupancy of the Smad complex to the LPA 1 gene promoter. (a) Cell extracts from MDA-MB-231 and SKOV-3 cells treated with TGFb (2.5 ng/ml) or vehicle for 1 h were incubated with biotinylated DNA fragment containing the À 401 TIE and strepatavidin beads. The DNA precipitates (DNAP) were subjected to western blot analysis for Smad3 and E2F4. Whole-cell lysates (WCL) were included as input. (b) ChIP assays were performed to examine the binding of Smad3 and E2F4 to the À 40 and À 401 TIEs of the LPA 1 promoter and to the c-myc TIE (positive controls). The immunoprecipitation of Smad3 and E2F4 was verified by western blotting analysis of immunoprecipitates and WCL. The binding was quantitated by qPCR using SYBR Green and the specific primers listed in Table 1 . The results were normalized to the C t values of inputs and presented as percentages of inputs. ND, not detectable. complex to the À 401 TIE of the LPA 1 gene promoter, a process analogous to the well-defined mode of repression of c-myc. 34 Among the multiple LPA receptors, LPA 1 is the only receptor subtype transcriptionally repressed by the TGFb-Smad signaling. In TGFb-challenged cells, Smad3 forms a large complex with E2F4/ 5-p107 and Smad4 in the cytoplasm, translocates to the nucleus and binds to the TIE motif where the complex recruits other corepressors and silences gene expression. 37 Hence, both Smadbinding site and the conjugated E2F4/5 element are instrumental to TGFb repression of target genes. 34 Extensive analysis of the promoter sequences of other LPA receptors does not identify any TIE consensus sequence in the LPA 4 , LPA 5 and LPA 6 promoters (Supplementary Figure S4) . There are putative repressive SBE in the LPA 2, and LPA 3 promoter sequences. However, none of these repressive SBEs is closely linked to a nearby E2F4/5 binding site. It is intriguing that the two TIE sites of the LPA 1 gene promoter do not function equally. The À 401 TIE was identified to be the major one for Smad-mediated repression of LPA 1 while the contribution of the À 40 TIE was negligible. This difference could be attributed to the fact that only 4 out of 11 nucleotides match with the consensus E2F4/5 sequence at the À 40 TIE while the À 401 TIE matches the consensus at 9 out of 11 nucleotides. Alternatively, the TIE location relative to the transcriptional initiation site or other regulatory sequences beyond the TIE sites could influence the interaction with the Smad complex and the transcriptional repression.
The biological function of LPA 1 has been a subject of extensive studies in both in vitro cell culture and genetic animal models. [8] [9] [10] 27 Compared with other LPA receptors, LPA 1 is most widely expressed. 3 The nearly ubiquitous distribution of LPA 1 has led to the assumption that LPA 1 is constitutively expressed. However, a few recent studies have hinted at the regulation of LPA 1 by intracellular and extracellular cues. 38, 39 The most exciting observation is that LPA 1 is one of the target genes repressed by the metastatic tumor suppressor Nm23. 20 Another study showed that germline polymorphism of FGFR4 (fibroblast growth factor receptor 4) at residue 388 (G388R) correlates with enhancement of LPA 1 expression and more aggressive migratory and invasive responses to LPA in tumors carrying R388 FGFR4. 40 Although LPA 1 expression may be indeed regulated by Nm23 and FGFR4, it is not known whether or how these modulators affect transcription, stability or translation of LPA 1 . The results from the current study represent the first example that an endogenous factor could transcriptionally restrain expression of LPA 1 and LPA 1 -dependent cellular effects.
The roles of LPA and LPA receptors in cancer have drawn considerable attention in recent years. The LPA 2 receptor is overexpressed in ovarian, breast, thyroid and rectal colon cancers. [15] [16] [17] [18] [19] The transgenic and knockout mouse models further support an oncogenic role of LPA 2 .
14,41 Expression of LPA 1 , on the other hand, does not show consensus increases from normal to malignant phenotypes. Instead, several independent groups have reported a tendency of downregulation of LPA 1 in diverse cancers 15, [17] [18] [19] 42, 43 in sharp contrast to the upregulation of LPA 2 in malignant diseases. The findings of the current study offer a plausible explanation to this phenomenon. The enhanced TGFb signaling during cancer development and progression may serve as a repressor of expression of LPA 1 but not other LPA receptors.
TGFb controls a multitude of biological activities in mammalian cells. It inhibits proliferation of epithelial cells and thus has a part in early tumor suppression. However, TGFb frequently fails to induce growth arrest in transformed epithelial cells. Instead, TGFb stimulates migration and invasion of cancer cells, thereby promoting the metastatic potential in advanced cancer. 44 This presumed effect of TGFb on tumor cell invasion and metastasis is largely based on in vitro assays involving only TGFb as a motogen. 45 The conclusion may not truly reflect the physiological role of TGFb in in vivo conditions where tumor cells are exposed to a complex mix of multiple chemokines, cytokines, nutrients and growth factors. We found in the current study that the effects of TGFb on cell motility could be opposite under different conditions. In the cancer cell lines we tested, TGFb itself was a weak stimulus of tumor cell invasion. In the presence of LPA, however, the role of TGFb was reversed, counteracting the strong motogenic activity of LPA. As both TGFb and LPA are present in the circulation and malignant effusions, TGFb probably acts as a negative regulator of cell motility in physiological and pathophysiological conditions. By extension, the findings of the current work underscore the importance of crosstalk between LPA and other coexisting factors in coordination of the overall cellular responses. Cell culture MDA-MB-231 was provided by Dr S Spiegel (Virginia Commonwealth University) and was maintained in Dulbecco modified Eagle medium (DMEM) with 10% FBS and 100 U/ml penicillin and 100 mg/ml streptomycin. IOSE-29 was originally obtained from Dr N Auersperg (University of British Columbia, Canada) and cultured as described previously. 46 Primary Mammary epithelial cells (1001-8) and primary ovarian epithelial cells (NOE-71) were provided by Dr Y Yu (MD Anderson Cancer Center) and were cultured in HuMEC Ready Medium (Invitrogen) and 50:50 M199/F12 medium with 10% FBS, 20 ng/ml EGF and gentamicin (10 mg/ml), respectively. MCF-10A was provided by Dr D Gewirtz (Virginia Commonwealth University) and cultured in DMEM/F12 medium with 5% horse serum, 10 mg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone. Other cancer cell lines used in the study were cultured in RPMI 1640 supplemented with 10% FBS and antibiotics as we described previously. 47 Migration and invasion assays Cell migration was measured using the transwell chambers (Costar, Corning, NY, USA). Transwells were coated with 10 mg/ml type I collagen and placed in the lower chamber containing serum-free medium supplemented with vehicle, TGFb, LPA or LPA þ TGFb. Cells suspended in serum-free medium containing 0.01% fatty acid-free bovine serum albumin were added to the upper chamber at 2 Â 10 4 cells/well. Cells were allowed to migrate for 6 h at 37 1C. Non-migrated cells were removed from the top filter surface with a cotton swab. Migrated cells attached to the underside of the Transwell were washed with PBS and stained with crystal violet and counted under a microscope. The invasion of tumor cell lines was measured using the growth factor-reduced Matrigel invasion chambers (BD Biosciences, San Jose, CA, USA). The assays were performed as migration assays except that the cells were incubated for 20 h. All migration and invasion assays were repeated three times with consistent results.
MATERIALS AND METHODS
shRNA shRNA-expressing lentivirus constructs were generated using pLV-RNAi vector (Biosettia, San Diego, CA, USA). The Smad3 target sequences LPA 1 is a novel target of TGFb J Wu et al were inserted to the pLV-RNAi plasmid following the manufacturer's protocol. The LPA 1 shRNA lentiviral vectors were obtained from Dr S Huang (Medical College of Georgia). 11 The shRNA lentiviruses were propagated in 293FT cells. The culture supernatants were used to infect cancer cell lines. The GFP-positive cells were sorted out using flow cytometer 96 h post virus infection. qPCR Total cellular RNA was isolated using Trizol (Invitrogen). Complementary DNA (cDNA) was synthesized from RNA (1 mg, random primers) using the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems. The mRNA levels of individual LPA receptors were determined using gene specific probes, the TaqMan Universal PCR Master Mix and the 7900HT Prism Real-Time PCR System (Applied Biosystems).
Luciferase vectors, deletion, and site-directed mutagenesis
The luciferase reporter vector pGL2-LPA 1 -Luc containing À 1156 to þ 86 was generated by PCR amplification of the LPA 1 promoter sequence (forward 5 0 -GCACTCGAGTGCAAAGCTACACTGGGAAA-3 0 , reverse 5 0 -GCAA AGCTTCACACTCTCACTGGCACTCG-3 0 ). The PCR product was inserted into pGL2-Basic-Luc at XhoI and HindIII sites. The deletion mutant ( À 366 to þ 86) was made by PCR amplification of the fragment from pGL2-LPA 1 -Luc (forward 5 0 -GCACTCGAGCTGACGCTCCCTGAGTGG-3 0 , reverse 5 0 -GCAAAG CTTCACACTCTCACTG-GCACTCG-3 0 ) and re-inserted into the pGL2-BasicLuc at the XhoI and HindIII sites. The promoter sequences in these plasmids were verified by automatic sequencing. The À 401 and À 40 TIE consensus sites within pGL-LPA 1 -Luc were converted into inactive sequences by sitedirected mutagenesis. The wild-type À 401 TIE 5 0 -GGCTTTGGCGCG-3 0 and wild-type À 40 TIE 5 0 -GGCTTCGCGC-3 0 were converted into 5 0 -GGCTA ATTCGCGC-3 0 and 5 0 -GGCAATTCGCC-3 0 , respectively. For luciferase assays, MDA-MB-231 and SKOV-3 were transfected with luciferase vectors along with b-gal plasmid using TransIT-LT1 (Mirus Bio). About 48-60 h after transfection, the cells were treated with TGFb or vehicle for 16-20 h. Cell extracts were prepared and assayed for luciferase activity using the luciferase assay kit from Promega (Madison, WI, USA).
DNA pull-down assay
Lysates of MDA-MB-231 and SKOV-3 cells were prepared by brief sonication in the HKMG buffer (10 mM, Tris-HCl, pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 0.1% NP-40 and protease inhibitors) using the Fisher Scientific Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA, USA), followed by 10 min of centrifugation at 12 000 g at 4 1C. Cellular proteins (400 mg) were incubated with 4 mg of biotinylated double-stranded oligonucleotides (5 0 -CCCTACTGCCCGGCTTTGGCGCGCTG GCAGGAGGAG-3 0 biotin) for 16 h at 4 1C. The M-280 Streptavidin Dynabeads (Invitrogen) (30 ml) were added to each sample and incubated for another hour at 4 1C. The Dynabeads were washed three times with PBS before western analysis of Smad3 or E2F4.
ChIP assay
TGFb or vehicle-treated MDA-MB-231 and SKOV-3 cells were cross-linked with 1% formaldehyde for 10 min at room temperature. The cells were lysed for 10 min in ice-cold lysis buffer (5 mM HEPES, pH 8.0, 80 mM KCl, 1% NP-40 and protease inhibitors). The nuclear fraction that was recovered by centrifugation (5 min at 5000 g) was resuspended in a ChIP assay buffer (50 mM HEPES, pH 8.0, 10 mM EDTA, 1% SDS, and protease inhibitors) and sonicated on ice to achieve an average chromatin length of 200-1000 bp. The sonicated samples were pre-cleared by incubation with Protein G Dynabeads (Invitrogen). The material recovered from the equivalent of 10 6 cells was incubated for 16 h at 4 1C with 2 mg of either normal rabbit IgG (Santa Cruz) or anti-Smad or anti-E2F4 antibodies. Protein G Dynabeads were added and incubated for 2 h. The DNA-protein-beads mixes were washed sequentially once with a low salt buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100), once with a high salt buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100), once with LiCl buffer (10 mM Tris-HCl, pH 8.0, 0.25 M LiCl, 1 mM EDTA, 1% deoxycholate, 1% NP-40), and finally twice with TE buffer (10 mM TrisHCl, pH 8, 1 mM EDTA). The specifically bound complexes were eluted from the Protein G Dynabeads by incubation twice for 15 min at 65 1C with TE elution buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA, 1% SDS). The immunoprecipitated complexes and the starting material (input) were incubated overnight at 65 1C to reverse cross linking, then treated with RNase A followed by proteinase K and purified using the QIAquick Spin Columns (Qiagen). The DNA samples were recovered in 100 ml H 2 O, and analyzed by qPCR using SYBR Green. Details of the primer used for qPCR were listed in Table 1 .
Statistics
All numerical data were presented as mean ± s.d. of triplicate assays, representative of three independent experiments. The statistical significances were analyzed using Student's t-test where Po0.05 was considered statistically significant. In all figures, the statistical significances were indicated with * if Po0.05 or ** if Po0.01. 
